Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:enzyme |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2002 |
| gptkbp:ATCCode |
V03AF07
|
| gptkbp:brand |
Elitek
Fasturtec |
| gptkbp:CASNumber |
133639-02-6
|
| gptkbp:contraindication |
gptkb:G6PD_deficiency
|
| https://www.w3.org/2000/01/rdf-schema#label |
rasburicase
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
catalyzes oxidation of uric acid to allantoin
|
| gptkbp:molecularWeight |
34 kDa
|
| gptkbp:origin |
recombinant DNA technology
|
| gptkbp:producedBy |
Aspergillus flavus (recombinant)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
allergic reactions
hemolysis in G6PD deficiency |
| gptkbp:target |
uric acid
|
| gptkbp:UNII |
Q10KZ7A4F7
|
| gptkbp:usedFor |
gptkb:tumor_lysis_syndrome
treatment of hyperuricemia |
| gptkbp:bfsParent |
gptkb:tumor_lysis_syndrome
|
| gptkbp:bfsLayer |
6
|